Although antibody treatment showed therapeutic efficacy at high doses, PLGA (PD-L1 siRNA+PD-1 siRNA)-NPs significantly inhibited tumor growth compared with the antibody treatment, even at low doses (online supplemental figure S5). Here, PDCD1 is linked to neoplasm.